MicroRNAs (miRNAs) are a class of endogenous small non-coding RNAs that play an important role in the pathogenesis and progression of tumor. Recently, it is discovered that circulating microRNA exist stably in body fluids, such as serum/plasma, cerebrospinal fluid, saliva, urine, breast milk and so on. Circulating microRNA profiles now have been associated with different hematologic malignancy types, disease states and prognosis. They may serve as a new class of non-invasive diagnostic or prognostic biomarkers, and even the potential therapeutic targets in hematologic malignancies. In this article, the circulating miRNA, existent pattern and function of circulating miRNA, and circulating miRNA and hematologic malignancies are reviewed.
Hematologic Neoplasms ; genetics ; Humans ; MicroRNAs

Most hematological tumors have high-grade malignancy and low cure rate, requiring new molecular markers for detection and evaluation. Circular RNAs (circRNAs) are a class of non-coding RNAs with covalently closed-loop structures, which participate in gene transcription and translation by binding to microRNAs and proteins. In recent years, with the deepening research on circRNAs, circRNAs have been found to play an important role in hematological malignancies. In this review, the latest research progress on the function and molecular mechanism of circRNAs in hematological malignancies was systematically summarized, and it was found that circRNAs may be potential new biomarkers and therapeutic targets in hematological malignancies.
Humans ; RNA, Circular ; MicroRNAs/genetics* ; Neoplasms ; Hematologic Neoplasms/genetics* ; Biomarkers

Hematologic Neoplasms ; genetics ; Humans ; Proto-Oncogene Proteins B-raf ; genetics

Long non-coding RNA (LncRNA) is defined as a class of transcripts more than 200 nucleotides in length and without the protein-coding function. It has been found for years, however, that little is known about the potential role of LncRNA in humans. But recent studies showed that LncRNA can regulate the coding-gene expression and participate in effects of human body. Accumulating evidence demonstrated that LncRNA are involved in cancer incidence, development and progression.With further exploration on the mechanisms of tumors, the relationship between the long non-coding RNA and hematological malignancies increasingly become a hot research. This review focuses on the mechanisms of LncRNA in hematological malignancies.
Hematologic Neoplasms ; genetics ; Humans ; RNA, Long Noncoding ; genetics

MicroRNA (miRNA) are small non-coding RNA that act at the post-transcriptional level, regulating protein expression by repressing translation mRNA target. They can be detected in plants, animal species and viruses, and are involved in numerous cellular processes. MicroRNA-155 (miR-155) which is a kind of microRNAs expressed in hematopoietic cells. Recent data indicate that MiR-155 plays a key role in the pathogenesis of hematological malignancies through regulating cell signal transduction pathways of cell proliferation, differentiation and apoptosis, acting predominantly as an oncomir. MiR-155 may be an important indicator to assess the diagnosis, treatment and prognosis of patients with hematological malignancies, including malignant lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It could be suggested that drugs such as antisense oligonucleotides able to down-regulate miR-155 expression would provide a novel, and possibly specific way to control the growth of a range of haematopoietic malignancies in conjunction with classical cytotoxic therapy. The purpose of this review is to summarize current findings on the role of miR-155 in hematopoietic malignancies and, moreover, to highlight their role as potential therapeutic tools.
Animals ; Hematologic Neoplasms ; genetics ; pathology ; therapy ; Humans ; MicroRNAs

DNA methylation is an important and reversible epigenetic modification which regulates genomic stability. Methylation is essential for mammalian development. Generally, gene expression level and DNA methylation are negative correlation. Transcriptional silencing via methylation of CpG islands in the promoter is important for cell growth and differentiation and plays a key role in tumorigenesis. Demethylation drug can modify chromatin and restore the ability of anti-oncogene. Demethylation therapy as a new therapy may treat efficiently hematological malignancies with resistance and relapse. In this review, DNA methylation mechanism, relationship between aberrant methylation and hematologic malignancies, mechanism of demethylation therapy, the advance of research on the demethylation therapy of hematological malignancies, such as acute and chronic leukemia, lymphoma, myelodysplastic syndrome were summarized.
DNA Methylation ; Hematologic Neoplasms ; genetics ; metabolism ; therapy ; Humans ; Methylation

The small RNAs include siRNA and miRNA. SiRNA is the splicing product of exogenous dsRNA by which to keep genome stability, while miRNA are processed from endogenous genome and work as a post-transcriptional regulator for gene expression. The small RNAs act in two ways: mediate degradation of of target RNA and inhibit translation of protein. The former requires the accurate complementation between small RNA and target RNA, while the latter requires only partial complementation. Which mechanism used depends on complementation degree, but not their origins. The RNAi as a technique for down-regulating target gene expression has been widely used in functional genomic studies and hematologic studies, especially for translocation-related fusion gene, apoptosis-related gene and MDR gene in leukemia. The results show that RNAi technique not only is the powerful tool for study mechanism but also has therapeutic potentials in clinic. Some studies reveal that changes of miRNA expression exist in many hematological malignancies and relate to known oncogenes, which indicates the miRNA is involved in pathogenesis of these diseases. This article reviews the discovery and effect of RNAi and small RNAs, as well as the similarities and differences between siRNA and miRNA, and focuses on the research of small RNAs in hematological malignancies.
Hematologic Neoplasms ; genetics ; Humans ; MicroRNAs ; genetics ; RNA ; genetics ; RNA Interference ; RNA, Small Interfering ; genetics

This article summarizes the progress of hematology in the recent tens years to show that experimental hematology used to pick up the 'hints' from clinical problems as the renewal of research directions and targets in experimental studies continuously. As the feedback, the results from lab investigations inserted into clinical practice and eventually made a quick modernization of hematology, which was actually a good model for the "translational research". The past few decades have witnessed tremendous advances in our understanding of normal hematopoiesis where genes dictate, epigenetics regulate, transcription factors mediate, and stem cells self-renew and differentiate. Dissection of disease pathogenesis not only elucidates molecular basis of disorders including hemoglobinopathy, aplastic anemia, hemophilia, hematopoietic malignancies such as leukemia and myeloproliferative disorders, but also provides therapeutic targets for drug development. Introduction of targeted therapies and combinatory targeting therapies greatly benefits hundreds of thousands of patients, and even turns acute promyelocytic leukemia from highly fatal to highly curable. In the 21st century the experimental hematology is entering the era of genomics and system biomedicine, and the pace of progress extrapolates to a prediction of hematologic neoplasms control in this century.
Animals ; Clinical Laboratory Techniques ; trends ; Hematologic Diseases ; genetics ; metabolism ; physiopathology ; Hematologic Neoplasms ; genetics ; metabolism ; physiopathology ; Hematology ; trends ; Humans

Enhancer of zeste homolog 2(EZH2) is a histone methyltransferase which regulate gene expression through epigenetic machinery. The abnormal expression of EZH2 has been described in many cancer types. With in-depth study, it was found that EZH2 is involved in the occurrence and development in many kinds of malignant hematologic disease which may play a dual role of oncogenes and tumor suppressor genes. In recent years, the emergence of EZH2 inhibitors provide a new option for the future treatment of hematological malignancies. In this review, the expression and clinical significance of EZH2 in various of hematological tumors were summarized briefly.
Enhancer of Zeste Homolog 2 Protein/genetics* ; Hematologic Neoplasms/genetics* ; Humans ; Neoplasms ; Oncogenes ; Research

The microRNAs (miRNAs) are an evolutionarily conserved class of 22 nucleotide (19 - 25 nt) non-coding RNAs. The miRNAs are partially complementary to 3' untranslated region of target mRNA, resulting in the repression of gene expression at post-transcriptional level. The miRNAs have been associated with diverse biological processes. This review summarizes recent progress of research on the characteristics and function of miRNAs, and the role of miRNAs in hematological malignancy development.
Gene Expression Regulation, Neoplastic ; genetics ; Hematologic Neoplasms ; genetics ; metabolism ; Humans ; MicroRNAs ; genetics ; physiology